Cargando…

Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G

Shigella is a major cause of moderate to severe diarrhea largely affecting children (<5 years old) living in low- and middle-income countries. Several vaccine candidates are in development, and controlled human infection models (CHIMs) can be useful tools to provide an early assessment of vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarkson, Kristen A., Frenck, Robert W., Dickey, Michelle, Suvarnapunya, Akamol E., Chandrasekaran, Lakshmi, Weerts, Hailey P., Heaney, Christopher D., McNeal, Monica, Detizio, Kate, Parker, Susan, Hoeper, Amy, Bourgeois, August L., Porter, Chad K., Venkatesan, Malabi M., Kaminski, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568644/
https://www.ncbi.nlm.nih.gov/pubmed/32968012
http://dx.doi.org/10.1128/mSphere.00988-19
_version_ 1783596565385969664
author Clarkson, Kristen A.
Frenck, Robert W.
Dickey, Michelle
Suvarnapunya, Akamol E.
Chandrasekaran, Lakshmi
Weerts, Hailey P.
Heaney, Christopher D.
McNeal, Monica
Detizio, Kate
Parker, Susan
Hoeper, Amy
Bourgeois, August L.
Porter, Chad K.
Venkatesan, Malabi M.
Kaminski, Robert W.
author_facet Clarkson, Kristen A.
Frenck, Robert W.
Dickey, Michelle
Suvarnapunya, Akamol E.
Chandrasekaran, Lakshmi
Weerts, Hailey P.
Heaney, Christopher D.
McNeal, Monica
Detizio, Kate
Parker, Susan
Hoeper, Amy
Bourgeois, August L.
Porter, Chad K.
Venkatesan, Malabi M.
Kaminski, Robert W.
author_sort Clarkson, Kristen A.
collection PubMed
description Shigella is a major cause of moderate to severe diarrhea largely affecting children (<5 years old) living in low- and middle-income countries. Several vaccine candidates are in development, and controlled human infection models (CHIMs) can be useful tools to provide an early assessment of vaccine efficacy and potentially support licensure. A lyophilized strain of S. sonnei 53G was manufactured and evaluated to establish a dose that safely and reproducibly induced a ≥60% attack rate. Samples were collected pre- and postchallenge to assess intestinal inflammatory responses, antigen-specific serum and mucosal antibody responses, functional antibody responses, and memory B cell responses. Infection with S. sonnei 53G induced a robust intestinal inflammatory response as well as antigen-specific antibodies in serum and mucosal secretions and antigen-specific IgA- and IgG-secreting B cells positive for the α4β7 gut-homing marker. There was no association between clinical disease outcomes and systemic or functional antibody responses postchallenge; however, higher lipopolysaccharide (LPS)-specific serum IgA- and IgA-secreting memory B cell responses were associated with a reduced risk of disease postchallenge. This study provides unique insights into the immune responses pre- and postinfection with S. sonnei 53G in a CHIM, which could help guide the rational design of future vaccines to induce protective immune responses more analogous to those triggered by infection. IMPORTANCE Correlate(s) of immunity have yet to be defined for shigellosis. As previous disease protects against subsequent infection in a serotype-specific manner, investigating immune response profiles pre- and postinfection provides an opportunity to identify immune markers potentially associated with the development of protective immunity and/or with a reduced risk of developing shigellosis postchallenge. This study is the first to report such an extensive characterization of the immune response after challenge with S. sonnei 53G. Results demonstrate an association of progression to shigellosis with robust intestinal inflammatory and mucosal gut-homing responses. An important finding in this study was the association of elevated Shigella LPS-specific serum IgA and memory B cell IgA responses at baseline with reduced risk of disease. The increased baseline IgA responses may contribute to the lack of dose response observed in the study and suggests that IgA responses should be further investigated as potential correlates of immunity.
format Online
Article
Text
id pubmed-7568644
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-75686442020-10-27 Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G Clarkson, Kristen A. Frenck, Robert W. Dickey, Michelle Suvarnapunya, Akamol E. Chandrasekaran, Lakshmi Weerts, Hailey P. Heaney, Christopher D. McNeal, Monica Detizio, Kate Parker, Susan Hoeper, Amy Bourgeois, August L. Porter, Chad K. Venkatesan, Malabi M. Kaminski, Robert W. mSphere Research Article Shigella is a major cause of moderate to severe diarrhea largely affecting children (<5 years old) living in low- and middle-income countries. Several vaccine candidates are in development, and controlled human infection models (CHIMs) can be useful tools to provide an early assessment of vaccine efficacy and potentially support licensure. A lyophilized strain of S. sonnei 53G was manufactured and evaluated to establish a dose that safely and reproducibly induced a ≥60% attack rate. Samples were collected pre- and postchallenge to assess intestinal inflammatory responses, antigen-specific serum and mucosal antibody responses, functional antibody responses, and memory B cell responses. Infection with S. sonnei 53G induced a robust intestinal inflammatory response as well as antigen-specific antibodies in serum and mucosal secretions and antigen-specific IgA- and IgG-secreting B cells positive for the α4β7 gut-homing marker. There was no association between clinical disease outcomes and systemic or functional antibody responses postchallenge; however, higher lipopolysaccharide (LPS)-specific serum IgA- and IgA-secreting memory B cell responses were associated with a reduced risk of disease postchallenge. This study provides unique insights into the immune responses pre- and postinfection with S. sonnei 53G in a CHIM, which could help guide the rational design of future vaccines to induce protective immune responses more analogous to those triggered by infection. IMPORTANCE Correlate(s) of immunity have yet to be defined for shigellosis. As previous disease protects against subsequent infection in a serotype-specific manner, investigating immune response profiles pre- and postinfection provides an opportunity to identify immune markers potentially associated with the development of protective immunity and/or with a reduced risk of developing shigellosis postchallenge. This study is the first to report such an extensive characterization of the immune response after challenge with S. sonnei 53G. Results demonstrate an association of progression to shigellosis with robust intestinal inflammatory and mucosal gut-homing responses. An important finding in this study was the association of elevated Shigella LPS-specific serum IgA and memory B cell IgA responses at baseline with reduced risk of disease. The increased baseline IgA responses may contribute to the lack of dose response observed in the study and suggests that IgA responses should be further investigated as potential correlates of immunity. American Society for Microbiology 2020-09-23 /pmc/articles/PMC7568644/ /pubmed/32968012 http://dx.doi.org/10.1128/mSphere.00988-19 Text en https://doi.org/10.1128/AuthorWarrantyLicense.v1This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.
spellingShingle Research Article
Clarkson, Kristen A.
Frenck, Robert W.
Dickey, Michelle
Suvarnapunya, Akamol E.
Chandrasekaran, Lakshmi
Weerts, Hailey P.
Heaney, Christopher D.
McNeal, Monica
Detizio, Kate
Parker, Susan
Hoeper, Amy
Bourgeois, August L.
Porter, Chad K.
Venkatesan, Malabi M.
Kaminski, Robert W.
Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G
title Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G
title_full Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G
title_fullStr Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G
title_full_unstemmed Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G
title_short Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G
title_sort immune response characterization after controlled infection with lyophilized shigella sonnei 53g
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568644/
https://www.ncbi.nlm.nih.gov/pubmed/32968012
http://dx.doi.org/10.1128/mSphere.00988-19
work_keys_str_mv AT clarksonkristena immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT frenckrobertw immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT dickeymichelle immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT suvarnapunyaakamole immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT chandrasekaranlakshmi immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT weertshaileyp immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT heaneychristopherd immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT mcnealmonica immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT detiziokate immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT parkersusan immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT hoeperamy immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT bourgeoisaugustl immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT porterchadk immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT venkatesanmalabim immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g
AT kaminskirobertw immuneresponsecharacterizationaftercontrolledinfectionwithlyophilizedshigellasonnei53g